[{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"Alzinova","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ALZ-101","moa":"Amyloid-beta-oligomer","graph1":"Neurology","graph2":"Phase I","graph3":"Alzinova","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alzinova \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alzinova \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ European Innovation Council","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ European Innovation Council"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AlzeCure Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ACD856","moa":"TRK receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AlzeCure Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"IRLAB","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRLAB \/ McQuade Center","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ McQuade Center"},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Emplicure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emplicure \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emplicure \/ Quotient Sciences"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"T20K","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB \/ Inapplicable"},{"orgOrder":0,"company":"Cyxone AB","sponsor":"Professor Rikard Holmdahl","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"T20K","moa":"AChE","graph1":"Neurology","graph2":"Phase I","graph3":"Cyxone AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cyxone AB \/ Professor Rikard Holmdahl","highestDevelopmentStatusID":"6","companyTruncated":"Cyxone AB \/ Professor Rikard Holmdahl"},{"orgOrder":0,"company":"Orexo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ketorolac Trometamol","moa":"COX","graph1":"Neurology","graph2":"Phase I","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orexo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orexo \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Fenja Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Fenja Capital","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Fenja Capital"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"IRLAB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"IRL757","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"IRLAB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"IRLAB \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IRLAB \/ Inapplicable"},{"orgOrder":0,"company":"Sinntaxis","sponsor":"Addex Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Dipraglurant","moa":"mGlu5 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Sinntaxis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sinntaxis \/ Addex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sinntaxis \/ Addex Therapeutics"}]
Find Neurology Drugs in Phase I Clinical Development in SWEDEN
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
